CAR-T vs. Bispecific Agents in the Treatment of Refractory Multiple Myeloma
In this video, “CAR-T vs. Bispecific Agents in the Treatment of Refractory Multiple Myeloma”, Sagar Lonial, MD, FACP, and Saad Usmani, MD, MBA, FACP, discuss anti-BCMA treatment strategies.
Targeting of BCMA is proving to be an effective strategy for multiple myeloma (MM). Promising BCMA-directed approaches include CAR T-cells and bispecific T-cell engagers, which have demonstrated impressive efficacy in refractory MM. However, there are advantages and disadvantages for each. Questions of where and how different BCMA-specific therapies may best fit among available options, now and in the future, are discussed.